New combo therapy shows promise for uterine condition in obese women
NCT ID NCT05172999
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a diabetes drug (polyethylene glycol loxenatide) to a hormone-releasing IUD (LNG-IUS) helps women with a precancerous uterine condition called endometrial atypical hyperplasia. The 30 participants were all obese and wanted to preserve their fertility or keep their uterus. The goal was to see if the combination led to a complete disappearance of abnormal cells within 32 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL ENDOMETRIAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, 200090, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?